CD9 and neoplasm: To trace the intracellular trafficking of EVs upon internalization by recipient cells, we engineered malignant FEMX-I and MDA tumor cells and primary MSCs to express CD9-GFP fusion protein, resulting in the production of in vivo-labeled EVs.